Patient Population Our base case analysis consisted of a hypothetical cohort of 65-year-old-women with low bone mineral density (BMD) (i.e., BMD of 2.5 or more standard deviations [SD] below the young adult mean) and a prevalent vertebral fracture. We assume that 21% of 65-to 69- year-olds fall into this study population.

INTRODUCTION Postmenopausal osteoporosis (PMO) is characterized by reduced bone mass leading to an increased risk of fracture. The prevalence of PMO increases with age from approximately 6% at age 50 to over 50% above age 80. The incidence of osteoporotic fractures follows a similar pattern, with wrist fractures peaking at approximately age 70, and vertebral [...]

Aspirin is the most widely used agent for the prevention of secondary stroke. The An-tiplatelet Trialists studied the effect of an-tiplatelet agents in more than 73,000 elderly patients with stroke and TIAs, unstable angina, and myocardial infarction as well as patients at high risk for other events of atherosclerotic ori-gin.22 Antiplatelet agents, as a whole, [...]

Immediately following an acute ischemic stroke, up to 5% of early deaths may be associated with deep venous thrombosis (DVT) or pulmonary embolism (PE). In addition, the NINDS Stroke Data Bank estimated that 30% of neurological worsening of stroke patients during hospitalization occurs in those with atherosclerotic etiologic factors. Therefore, theoretical advantages for anticoagu-lation therapy [...]

Age, sex, race, and family history are nonmodifiable risk factors for cerebrovascular events. Therefore, older patients (i.e., 65 years and above) are at higher risk for stroke-associated mortality and morbidity. Other factors associated with increased risk of stroke include hypertension, blood pressure differences in each arm, heart disease, carotid bruits, diabetes, dyslipidemia, elevated fibrinogen levels, [...]

INTRODUCTION Stroke is a major cause of death and disability among the elderly, typically defined as individuals over the age of 65. More than 750,000 Americans experience strokes annually, and 160,000 of these do not survive. Of the survivors, approximately one-third experience another stroke within five years.

In a randomized, double-blind, placebo-controlled study (PRISM-2) of interferon | -1a in patients with RRMS, 560 participants were randomly assigned to receive subcutaneous interferon | -1a 22 mcg (n = 189), 44 mcg (n = 184), or placebo (n = 187) three times a week for two years. The mean number of relapses during the [...]